Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.59% [1] - Net profit reached 87.38 million yuan, showing a year-on-year growth of 20.92% [1] - The company attributed its performance to ongoing refined operational management measures [1] Company Overview - The company is a data-driven clinical research service provider, focusing on the management of clinical trial site organizations (SMO) [1] - It has served over 960 clinical trial institutions and has the capability to cover more than 1,300 institutions across over 200 cities in China [2] - As of the reporting period, the company had undertaken over 4,200 international and domestic SMO projects, with 2,538 projects currently in execution [2] Market Demand and Performance - The company noted a positive recovery in industry and client demand, with a significant increase in inquiry volume and new contracts [1] - The new signed contracts (excluding tax) amounted to 600 million yuan, reflecting a year-on-year increase of 40.12% [2] - The company’s backlog of contracts (excluding tax) stood at 1.998 billion yuan, up 9.45% year-on-year as of June 2025 [2] Industry Landscape - The SMO industry in China is entering a new development phase, with leading SMO companies expanding their client resources, professional talent, and research institution coverage [3] - There is an increasing concentration in the industry as smaller SMO companies begin to exit the market, benefiting larger firms with stronger technical barriers and brand influence [3]
普蕊斯三季度净利同比增20.92% 新签订单同比实现较快增长